Sep 27, 2023 12:03PM
Apr 27, 2023 12:00PM
Sep 22, 2022 12:53PM
Mar 30, 2022 12:00PM
Mar 30, 2022 12:00PM
Jan 31, 2022 12:00PM
Jan 31, 2022 12:00PM OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101
Sep 21, 2021 12:19PM
Sep 21, 2021 12:00PM
Apr 26, 2021 12:00PM
Apr 26, 2021 12:00PM
Mar 26, 2021 01:00PM
Mar 26, 2021 01:00PM
Sep 17, 2020 12:00PM OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update
Sep 17, 2020 12:00PM
Mar 26, 2020 01:00PM
Mar 26, 2020 01:00PM
Mar 17, 2020 01:08PM
Mar 17, 2020 01:00PM
Sep 5, 2019 12:00PM
Sep 5, 2019 12:00PM OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update
Mar 28, 2019 01:00PM
Mar 28, 2019 01:00PM
Feb 7, 2019 12:00PM
Feb 7, 2019 12:00PM
Sep 6, 2018 12:00PM
Sep 6, 2018 12:00PM
Mar 28, 2018 12:07PM OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products
Mar 28, 2018 12:00PM
Sep 7, 2017 12:00PM
Apr 5, 2017 02:00AM
Apr 5, 2017 02:00AM
Mar 28, 2017 12:12PM
Mar 28, 2017 12:00PM
Feb 21, 2017 04:37PM OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting
Feb 21, 2017 12:00PM
Feb 7, 2017 12:00PM
Jan 24, 2017 12:15PM
Jan 4, 2017 11:45AM
Nov 28, 2016 11:45AM
Nov 17, 2016 11:45AM
Nov 15, 2016 11:45AM Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
Nov 15, 2016 11:45AM
Nov 15, 2016 02:00AM
Oct 24, 2016 11:45AM
Oct 4, 2016 11:45AM
Sep 20, 2016 11:45AM
Sep 15, 2016 11:45AM
Sep 8, 2016 11:45AM OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones
Aug 30, 2016 11:45AM

1,155,357 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All